📰 Priority Review News
Page 67 - Priority Review News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Priority Review. Real-time updates on events, politics, business and more.
March 31, 2023
TOKYO and CAMBRIDGE, Mass., Mar 31, 2023 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced today that three additional detailed analyses from the Phase IIb clinical study (Study
March 31, 2023
STOCKHOLM, March 31, 2023 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai...
March 31, 2023
/PRNewswire/ -- BioArctic ABs (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today the publication of additional detailed analyses from the phase...
March 31, 2023
STOCKHOLM, March 31, 2023 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai...
March 30, 2023
Western Resource Advocates está agora contratando para a vaga de Equity and Community Engagement Manager em Denver. Inscreva-se agora.
March 30, 2023
The FDA has approved Narcan (naloxone HCl) Nasal Spray as an over-the-counter emergency treatment for known or suspected opioid overdose.
March 29, 2023
The FDA has approved Narcan (naloxone HCl) Nasal Spray as an over-the-counter emergency treatment for known or suspected opioid overdose.
March 27, 2023
The FDA has approved Joenja® (leniolisib) for the treatment of activated phosphoinositide 3-kinase delta syndrome in patients aged ≥12 years.
March 24, 2023
USA News Group – It’s estimated that 6.7 million Americans over 65 (or more than 1 in 9 seniors) are now living with Alzheimer’s Disease (AD), and the number of diagnoses is on the rise. It’s expected that the burden of those ...
March 24, 2023
APDS (activated phosphoinositide 3-kinase delta (PI3Kd) syndrome) is a rare and progressive primary immunodeficiency Joenja® is a targeted treatment of APDS for adult and pediatric patients